954 THE ADDITION OF ESTRAMUSTINE TO PREDNISONE/DOCETAXEL FOR PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER P/D FAILURE: A SINGLE-CENTER EXPERIENCE

Zhong-Quan Sun

DOI: https://doi.org/10.1016/j.juro.2013.02.535

IF: 7.6

2013-01-01

The Journal of Urology

Abstract:You have accessJournal of UrologyProstate Cancer: Advanced (III)1 Apr 2013954 THE ADDITION OF ESTRAMUSTINE TO PREDNISONE/DOCETAXEL FOR PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER P/D FAILURE: A SINGLE-CENTER EXPERIENCE Zhong-Quan Sun Zhong-Quan SunZhong-Quan Sun Shanghai, China, People's Republic of More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2013.02.535AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES To investigate the efficacy and safety of Estramustine/Prednisone/ Docetaxel combination (E/P/D) as salvage chemotherapy for patients with metastatic castration-resistant prostate cancer (mCRPC) after the failure of Prednisone/Docetaxel (P/D). METHODS 42 mCRPC patients for whom P/D treatment had failed received E/P/D combination between November 2005 to July 2011. A decrease of >50% in serum PSA level was set as the primary endpoint. The toxicity profiles were also reviewed. RESULTS Patients received a total of 193 cycles of E/P/D treatment. All 42 cases were eligible for safety analysis, and 39 cases were eligible for the evaluation of treatment effect. 66.7% (26/39) patients had treatment response. The median biochemical progression-free survival was 16.7 weeks, and the median overall survival was 59.6 weeks. Patients who response to the previous E monotherapy or initiating E/P/D treatment after second line hormonal therapy had a significantly higher incidence of PSA response to E/P/D therapy, despite no significant effect of other factors examined on the PSA response to E/P/D therapy. Furthermore, the overall survival in responders to E/P/D therapy was significantly better than that in nonresponders. Despite grade 3/4 neutropenia in 31.0% of patients, this combination was in general tolerable. CONCLUSIONS Estramustine/Prednisone/Docetaxel combination is relatively active with acceptable toxicity profile as salvage treatment for mCRPC patients after the failure of P/D, Particularly for those response to the previous E monotherapy or initiating E/P/D treatment before third line hormonal therapy. © 2013 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 189Issue 4SApril 2013Page: e391 Advertisement Copyright & Permissions© 2013 by American Urological Association Education and Research, Inc.MetricsAuthor Information Zhong-Quan Sun Shanghai, China, People's Republic of More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...